The goal of this clinical trial is to compare the effects of different modes and frequencies of transcutaneous auricular vagus nerve stimulation (taVNS) on motor and non-motor symptoms in people with Parkinson's disease. The main questions it aims to answer are: Which mode and frequency of taVNS is most effective in improving motor or non-motor symptoms? Are there any side effects or safety concerns with different taVNS frequencies? Researchers will compare three types of taVNS: 25 Hz non-expiratory gated, 25 Hz expiratory gated, and 100 Hz expiratory gated stimulation. Participants will: Receive each type of taVNS in three 2-week cycles, with 2-month breaks between cycles Undergo neuropsychological assessments, imaging, eye-tracking, and biological sample collection before and after each cycle.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Unified Parkinson's Disease Rating Scale Part III (UPDRS-III)
Timeframe: Baseline;2 weeks; 10 weeks; 12 weeks;20 weeks;22weeks
Non-Motor Symptoms Scale, Second Version (NMSS-2)
Timeframe: Baseline;2 weeks; 10 weeks; 12 weeks;20 weeks;22weeks